CELLULAR IMMUNOTHERAPIES

At the end of the beginning: immunotherapies as living drugs

The American Course on Drug Development and Regulatory Science and the US National Institutes of Health held a workshop on cell-based immunotherapy on 22 January 2019.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: CAR-T therapy.
Fig. 2: Approaches in various stages of development.
Fig. 3: Duration of remission, event-free survival, and overall survival of pediatric and young-adult patients with ALL given infusion of Kymriah.

Change history

  • 06 August 2019

    An amendment to this paper has been published and can be accessed via a link at the top of the paper.

References

  1. 1.

    Mezher, M. Regulatory Affairs Professional Society https://www.raps.org/news-and-articles/news-articles/2019/1/gottlieb-marks-detail-plans-to-advance-developmen?utm_source=MagnetMail&utm_medium=Email%20&utm_campaign=Focus%20on%20Biotech%3A%20January (2019).

  2. 2.

    Sadelain, M. Cell 171, 1471 (2017).

  3. 3.

    Maude, S. L. et al. N. Engl. J. Med. 378, 439–448 (2018).

  4. 4.

    Maude, S. L. et al. N. Engl. J. Med. 371, 1507–1517 (2014).

  5. 5.

    Grupp, S.A. 60th American Society of Hematology Annual Meeting, abstr. 895 (2018).

  6. 6.

    Cherkasova, E., Weisman, Q. & Childs, R. W. Front. Oncol. 3, 243 (2013).

  7. 7.

    Takahashi, Y. et al. J. Clin. Invest. 118, 1099–1109 (2008).

  8. 8.

    Porter, D. L. et al. Sci. Transl. Med. 7, 303ra139 (2015).

  9. 9.

    Lee, D. W. et al. Biol. Blood Marrow Transplant. 25, 625–638 (2019).

  10. 10.

    Maude, S. L., Barrett, D., Teachey, D. T. & Grupp, S. A. Cancer J. 20, 119–122 (2014).

  11. 11.

    Teachey, D. T. et al. Cancer Discov. 6, 664–679 (2016).

  12. 12.

    Grupp, S. A. et al. N. Engl. J. Med. 368, 1509–1518 (2013).

  13. 13.

    Vodnala, S.K. et al. Science 363, (2019).

  14. 14.

    Rosenberg, S. A. & Restifo, N. P. Science 348, 62–68 (2015).

  15. 15.

    Gattinoni, L., Klebanoff, C. A. & Restifo, N. P. Nat. Rev. Cancer 12, 671–684 (2012).

  16. 16.

    Gautam, S. et al. Nat. Immunol. 20, 337–349 (2019).

  17. 17.

    Sade-Feldman, M. et al. Cell 175, 998–1013.e20 (2018).

  18. 18.

    Eyquem, J. et al. Nature 543, 113–117 (2017).

  19. 19.

    Ellis, J. Hum. Gene Ther. 16, 1241–1246 (2005).

  20. 20.

    Rivière, I., Dunbar, C. E. & Sadelain, M. Blood 119, 1107–1116 (2012).

  21. 21.

    von Kalle, C., Deichmann, A. & Schmidt, M. Hum. Gene Ther. 25, 475–481 (2014).

  22. 22.

    Xu, Z., Park, Y., Zhen, B. & Zhu, B. Stat. Med. 37, 4589–4609 (2018).

  23. 23.

    Xu, Z., Zhen, B., Park, Y. & Zhu, B. Stat. Med. 36, 592–605 (2017).

  24. 24.

    Tran, E., Robbins, P. F. & Rosenberg, S. A. Nat. Immunol. 18, 255–262 (2017).

  25. 25.

    Cafri, G. et al. Nat. Commun. 10, 449 (2019).

  26. 26.

    Flying machines which do not fly. The New York Times https://newspaperarchive.com/new-york-times-oct-09-1903-p-6/ (1903).

  27. 27.

    Wright, O. Diaries and Notebooks: Orville Wright. Library of Congress https://www.loc.gov/item/wright002238/ (1903).

Download references

Acknowledgements

We thank all the speakers, panelists, and organizers who made this workshop possible: Greg Campbell (GCStat Consulting), Cathy Cantilena (NIH), Natalie DeWitt (Accendo Scientific and NDA Partners), David DiGiusto (Semma Therapeutics), Jaikumar Duraiswamy (OTAT, FDA), Ellen Feigal (NDA Partners and Arizona State University), Thomas Fellner (Lonza Pharma & Biotech), Brett Giroir (US Department of Health and Human Services) Stephan Grupp (CHOP), Jaime Kenyon (American Course on Drug Development and Regulatory Science and the University of California, San Francisco), Harvey Klein (NIH), Telba Irony (CBER, FDA), Roger Kurlander (CBER, FDA), Crystal Mackall (Stanford University), Jorge-Mansilla-Soto (Memorial Sloan Kettering Cancer Center), Peter Marks (CBER, FDA), Carl Peck (NDA Partners and the University of California, San Francisco), Nicholas Restifo (NCI), Steven Rosenberg (NCI), Nirali Shah (NCI), David Stroncek (NIH), and Allen Wensky (OTAT, FDA, CBER). The full list of speakers and ‘slide decks’ for most of the presentations are on the website of the University of California, San Francisco, American Course on Drug Development and Regulatory Science (https://pharm.ucsf.edu/acdrs/events/acdrs-nih-workshop-cell-based-immunotherapy-bench-bedside-beyond).

Author information

Correspondence to Ellen G. Feigal.

Ethics declarations

Competing interests

E.G.F. directs the Biologics Practice at NDA Partners and is on the board of directors of the ARM Foundation for Cell and Gene Medicine.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark